Is Rigel Pharmaceuticals, Inc. overvalued or undervalued?

As of 4 March 2025, Rigel Pharmaceuticals, Inc. has moved from a risky to a very attractive valuation grade. The company is currently undervalued, as indicated by its P/E ratio of 10, which is significantly lower than the industry average. Additionally, the EV to EBITDA ratio stands at 7.92, and the PEG ratio is exceptionally low at 0.01, suggesting strong growth potential relative to its price.
In comparison with peers, Rigel Pharmaceuticals shows a more favorable valuation with a P/E of 9.21 compared to Eagle Pharmaceuticals, which has a P/E of 2.15, and 2seventy Bio, Inc. at 76.93. The company's impressive ROCE of 2630.60% and ROE of 200.24% further support the notion that it is undervalued. Despite a recent decline in stock price compared to the S&P 500, Rigel's one-year return of 98.37% indicates strong performance, reinforcing its attractive valuation.